The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice. 2018

Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman. Electronic address: yousufm@squ.edu.om.

This study aimed at investigating the possible ameliorative effects of sitagliptin in mice with gentamicin (GEN) nephrotoxicity. Sitagliptin was given to the animals at an oral dose of 10mgkg-1 per day for 10days, and in some of these mice, GEN was injected intraperitoneally at a dose of 100mgkg-1 per day during the last seven days of the treatment. Nephrotoxicity was evaluated histopathologically by light microscopy and biochemically by measuring several indices in plasma, urine and renal cortex homogenates. GEN treatment induced nephrotoxicity as evidenced by significantly (P<0.0001) increasing the plasma concentrations of urea, creatinine, circulatory cytokines, cystatin C, sclerostin, and TNFα. Treatment with GEN also significantly elevated urinary N-acetyl-β-d glucosaminidase (NAG) concentration (P<0.0001). Moreover, GEN caused significant increase in oxidative stress in the kidneys (P<0.0001). Histopathological examination revealed massive tubular injury, necrosis, infiltration of inflammatory cells and intraluminal hyaline casts in mice treated with GEN. Sitagliptin alone did not significantly affect any of the indices measured. However, concomitant treatment with sitagliptin and GEN significantly mitigated most of the nephrotoxic actions of GEN. Pending further studies, sitagliptin may potentially be useful as a nephroprotectant agent.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007672 Kidney Cortex The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL. Cortex, Kidney
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D000068900 Sitagliptin Phosphate A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES. 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine,Januvia,MK 0431,MK-0431,MK0431,Sitagliptin,Sitagliptin Monophosphate Monohydrate,Sitagliptin Phosphate Anhydrous,Sitagliptin Phosphate Monohydrate,0431, MK,Anhydrous, Sitagliptin Phosphate,Monohydrate, Sitagliptin Monophosphate,Monohydrate, Sitagliptin Phosphate,Monophosphate Monohydrate, Sitagliptin,Phosphate Anhydrous, Sitagliptin,Phosphate Monohydrate, Sitagliptin,Phosphate, Sitagliptin
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
July 2007, Diabetes care,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
February 2016, Oncology reports,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
April 2007, Drug metabolism and disposition: the biological fate of chemicals,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
May 2020, Aging and disease,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
April 2007, Drug metabolism and disposition: the biological fate of chemicals,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
June 2011, Journal of the American Geriatrics Society,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
January 2017, Mediators of inflammation,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
June 2014, International journal of molecular sciences,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
September 2007, Biopharmaceutics & drug disposition,
Yousuf M Al Suleimani, and Aly M Abdelrahman, and Turan Karaca, and Priyadarsini Manoj, and Mohammed Ashique, and Abderrahim Nemmar, and Badreldin H Ali
January 2012, Dermatology (Basel, Switzerland),
Copied contents to your clipboard!